Close

Valeant Pharma (VRX) Comments on Press Reports; Says Fully Cooperating with Authorities

Go back to Valeant Pharma (VRX) Comments on Press Reports; Says Fully Cooperating with Authorities

Valeant (VRX) 3Q Earnings Preview: Underlying RX Trends Remain Weak - Wells Fargo

November 1, 2016 7:54 AM EDT

Wells Fargo analyst David Maris issued a Q3 preview of Valeant Pharmaceuticals (NYSE: VRX), saying while the company should have some tailwinds for 3Q including price increases, cost cuts, and a now fixed Walgreens deal; however, Valeant's underlying U.S. prescription trends remain... More

Volatility and Volume movement

October 31, 2016 4:30 PM EDT

IPath S&P 500 VIX Short-Term Futures (VXX) up 71c to 34.14

CBOE Volatility Index (VIX) up 87c to 17.06

Actives: AAPL FB BABA BAC GE MSFT AMZN INTC TSLA NFLX TWTR CVX DB PFE XOM NKE MET VRX

... More

Valeant Pharma (VRX) Trades at New Lows Amid Ex-Executive Probe

October 31, 2016 3:59 PM EDT

Valeant Pharma (NYSE: VRX) is trading at fresh 52-week lows following reports ex-CEO, Michael Pearson and ex.-CFO, Howard Schiller, are the focus of criminal probe related potential accounting fraud tied to the company's hidden Philidor Rx Services company.

Shares last traded down 12.4% to $17.83.

... More